Noticias y eventos

• Las nuevas instalaciones amplían las oportunidades de aprendizaje práctico, desarrollo profesional y colaboración clínica.
• BVI tiene previsto ampliar la oferta formativa del Hub mediante programas estructurados centrados en cirugía de cataratas, glaucoma y retina, lentes intraoculares premium y desarrollo de la práctica clínica.

SANT CUGAT, España, 15 de junio de 2026 — A medida que la oftalmología se vuelve cada vez más especializada y dependiente de la tecnología, continúa creciendo la demanda de formación quirúrgica práctica. Para responder a esta necesidad, BVI anunció hoy la apertura del BVI Experience Hub, un espacio dedicado a la formación oftalmológica, el desarrollo profesional y la colaboración clínica para cirujanos y equipos clínicos de Europa y de todo el mundo. Leer más

• El consejo actuará como grupo asesor, proporcionando a BVI orientación sobre conocimiento del mercado, práctica clínica y formación quirúrgica en toda Europa.
• La iniciativa se basa en el impulso generado por el Surgical Leadership Council de BVI en Estados Unidos, ampliando su modelo de colaboración a mercados europeos clave.

WALTHAM, Massachusetts, 6 de mayo de 2026 — BVI, compañía global especializada en dispositivos oftalmológicos, anunció hoy la creación de su European Surgical Leadership Council. El grupo está formado por siete cirujanos, figuras destacadas en sus respectivos campos, que representan las especialidades de segmento anterior, glaucoma y cirugía vitreorretiniana en mercados europeos clave. Leer más

Leer más

Waltham, MA., 19 de enero de 2026 - BVI, líder mundial en el mercado de dispositivos oftálmicos, ha anunciado hoy el nombramiento de Jim Hollingshead como presidente y director general (President & Chief Executive Officer). Hollingshead sucede a Shervin Korangy, que continuará como asesor de BVI y comenzará una nueva función como asesor principal de TPG Capital. Leer más

• BVI announces Virtuoso®, its first dual-function phaco-vitrectomy system designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• European debut planned for 2025 Global ophthalmic congresses in Europe (Euretina and ESCRS).  

Waltham, Mass., September 3, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling of its innovative phaco-vitrectomy surgical platform, Virtuoso®, a dual-function system designed for both cataract and vitreoretinal procedures. Leer más

• BVI received four awards in the 2025 Medical Device Network Excellence Awards—for Innovation, Product Launches, R&D, and Investments—recognizing its leadership in advancing ophthalmic technology and global growth.
• Key achievements include the launch of SERENITY IOLs with ISOFOCAL technology, FDA clearance of the Leos™ glaucoma system, and a $1 billion capital raise supporting strategic expansion and continued innovation.

WALTHAM, Mass., July 9th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, has been recognized with four prestigious accolades in the 2025 Medical Device Network Excellence Awards. The company earned top honors in Innovation, Research and Development, Investments, and Product Launches, underscoring its leadership in advancing eye care technology, strategic growth, and breakthrough product development. Leer más

• Positions company for several new product launches and scaling of operations to meet rising demand globally
• $1 billion of new capital raised to refinance debt and fund accelerated growth

Waltham, MA, March 10, 2025 – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the completion of a $1 billion strategic capital raise in partnership with TPG, a leading global alternative asset management firm. This investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, strengthens the company’s financial position as it looks to accelerate product innovation and expand its global footprint. Leer más

BVI to Launch New SERENITY and SERENITY Toric Premium Monofocal IOLs, Delivering an Extended Range of Vision to More Patients, at the 2024 ESCRS Leer más

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BVI, one of the fastest-growing, diversified surgical ophthalmic businesses in the world, announced the acquisition of Medical Mix, a company specializing in the supply of medical devices for ophthalmic surgery across Spain and Portugal. Leer más

WALTHAM, Mass. — July 18^th, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.  This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership. Leer más

• FINEVISION HP is the first patented diffractive trifocal IOL and is one of the flagship products in BVI’s IOL portfolio; FINE Trifocal technology is utilized across the company’s entire range of presbyopia-correcting IOLs.
• The Japan launch follows two key FINEVISION HP 2023 milestones: One million FINEVISION IOL implants sold worldwide and the recent completion of the FINEVISION HP IDE clinical study patient enrollment in the US.
• BVI expects to introduce several IOL models over the next few years in Japan, demonstrating BVI’s commitment to ophthalmic surgeons and their patients in Japan.

WALTHAM, Mass., June 19^th, 2023 (GLOBE NEWSWIRE) BVI, one of the fastest growing surgical ophthalmic businesses in the world, is thrilled to announce the official launch of FINEVISION HP in Japan. The FINEVISION HP hydrophobic and glistening free trifocal IOL represents a significant breakthrough in trifocal technology as the first trifocal platform to offer cataract patients high quality vision across all distances.  Leer más

WALTHAM, MA - May 1, 2023 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced it has completed enrollment of its U.S. Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal intraocular lens, FINEVISION® HP.  Leer más

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). Leer más